MedTrace Logo

CY503 for the Treatment of Malignant Melanoma Stage IV After Failure of Prior Therapy

NCT00658437 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 31

Last updated 2011-06-08

No results posted yet for this study

Summary

The trial is designed as a phase II evaluation of the effect of CY-503 on progression free survival (PFS) in patients with stage IV malignant melanoma after failure of prior therapy. The aim of the study is at least a rate of 25% (PFS \>/= 3 months).

Conditions

Interventions

DRUG

CY-503

solution for subcutaneous injection, 350 ng twice weekly

Sponsors & Collaborators

  • Cytavis Biopharma GmbH

    lead INDUSTRY

Principal Investigators

  • Peter Mohr, MD · Elbe Klinikum Buxtehude, Germany

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
90 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2008-04-30
Primary Completion
2009-08-31
Completion
2010-05-31

Countries

  • Germany

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00658437 on ClinicalTrials.gov